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for Acid Related Disorders (DARD) after the reimburse-
ment of rofecoxib and celecoxib. The substances con-
sidered were: NSAID: aceclofenac, acemetacin,
diclofenac, ibuprofen, indometacin, meloxicam, nabume-
ton, naproxen, nimesulide, piroxicam, tenoxicam; Proton
Pump Inhibitors: omeprazol, pantoprazol, lansoprazol,
rabeprazol, esomeprazol; H2 Receptor Antagonists: cime-
tidine, famotidine, nizatidine, ranitidine; misoprolol and
sucralfate were also studied. METHODS: Using data of
reimbursed medicines dispensed in the NHS (in DDD
units) from January 1995 to June 2001, modelling was
performed using SARIMA models. Intervention variables
were used to evaluate the inﬂuence of the reimburse-
ment of Cox2 inhibitors on overall NSAID and DARD
consumption. RESULTS: NSAID overall consumption
increased for the considered time period from 50.49
DDD/1.000 inhabitants/day in year 2000 to 62.35
DDD/1.000 inhabitants /day 1° semester 2001. DARD
consumption also increased from 24.87 DDD/1.000
inhabitants/day to 28 DDD/1.000 inhabitants /day during
the above mentioned period of time. CONCLUSIONS:
The global dispensing of selected NSAID in 1° semester
2001 faced a total increase above the projected value. The
Cox2 inhibitors appear to have an add-on effect, rather
than a substitutive effect on already existing therapies.
Moreover we did not observe decrease on DARD con-
sumption patterns.
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OBJECTIVES: Rheumatoid Arthritis (RA) is a chronic
disease, whose social burden is mostly related to costs
that increase with the progression of illness severity and
related disability. Thus it is possible that early treatment
induces signiﬁcant cost savings. Recently favourable cost-
effectiveness ratios were demonstrated for Etanercept
(ETA) versus Inﬂiximab plus Methotrexate (INFLI +
METHO) for early RA treatment, in severe US patients
previously untreated with METHO. An adaptation of the
US model to Italy was undertaken, in order to evaluate
cost-effectiveness of ETA, in the Italian National Health
care System (NHS) perspective (direct medical costs).
METHODS: Cost-effectiveness analysis compared ETA
25mg twice weekly with INFLI 3mg/kg or 10mg/kg
(mean patient weight 74Kg was assumed, from clinical
trials) q4 or q8 weeks plus oral METHO (16mg/week).
Time horizon was established at two years, according to
published long-term follow-up clinical data. Also, drug
dosages, efﬁcacy and probabilities of events were based
on published clinical trial data. Market prices were
applied for medication costs plus ofﬁcial tariffs for IV
administration and monitoring for INFLI and METHO.
For sepsis as a major adverse event, the NHS hospital
tariff was used. The total per patient cost was then cal-
culated and the cost-effectiveness ratio was expressed as
cost/patient to prevent radiographycally detected RA pro-
gression. RESULTS: Total cost/patient for ETA was lower
compared to INFLI + METHO at different dosages
(respectively, €25,931 vs from €44,745 to €119,215,
depending on INFLI schedule), with the only exception
of INFLI 3mg/kg q8 weeks (€24,189). Cost-effectiveness
ratio (cost/patient successfully treated) was €41,160 for
ETA vs values in the range of €56,122 to €218,743 
for INFLI + METHO. CONCLUSIONS: ETA was found
dominant (less costly and more effective) versus 3 differ-
ent dosages of INFLI + METHO, and showed a positive
cost-effectiveness ratio versus INFLI 3mg/kg q8 weeks, in
the perspective of the Italian NHS.
PAR5
THE TOTAL COSTS OF TREATMENT WITH
VALDECOXIB COMPARED TO GENERIC
DICLOFENAC ARE SIMILAR IN PATIENTS WITH
RHEUMATOID ARTHRITIS IN GERMANY
von Scheele B1, DePlatchett J1, Gaffney L2, Peña BM3,
Niculescu L3
1RTI Health Solutions, Research Triangle Park, NC, USA; 2RTI
Health Solutions, Manchester, United Kingdom; 3Pﬁzer Inc,
New York, NY, USA
OBJECTIVES: To conduct a cost-consequence analysis
evaluating the treatment cost difference between valde-
coxib and diclofenac in rheumatoid arthritis (RA) treat-
ment from the perspective of German Sickness funds.
METHODS: Health care resource utilization data were
prospectively collected in a double-blind randomized trial
of oral valdecoxib 20mg QD (n = 246) versus diclofenac
75mg BID (n = 237) of adult patients with RA in 26
countries. The study demonstrated that valdecoxib has a
superior GI safety proﬁle and comparable efﬁcacy to
diclofenac. The Health care resource data were costed
using published German sources. Information evaluated
medications, hospitalizations, unscheduled consultations
with Health care professionals and use of diagnostic and
medical procedures. Pharmacy costs of valdecoxib and
generic diclofenac were included. In-depth analyses were
conducted to explore the cost-difference attributable to
gastrointestinal (GI) serious adverse events (GI-SAEs).
The results are presented in cost per patient during the
study period and cost per patient per day of treatment in
order to adjust for the lower withdrawal rates with valde-
coxib. RESULTS: The fewer hospitalization days in
valdecoxib patients translated into signiﬁcantly lower
hospitalization cost per patient for valdecoxib with a 
cost difference of €138.17 (95% conﬁdence interval [CI]:
€282.84, €10.58). The total Health care costs per patient
over a 6-month period for valdecoxib (€659.45) com-
pared to diclofenac (€549.31) showed a cost difference 
of €110.14 (95% CI: €70.33, €290.62). Accounting for
the different withdrawal rates (patients stayed longer on
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valdecoxib), valdecoxib had a lower cost (€0.26) per
treatment day (95% CI: €-3.23, €2.72). The cost differ-
ence associated with GI-SAEs per treatment day was
lower for valdecoxib: €1.57 (95% CI; €3.90, €0.75).
CONCLUSIONS: Valdecoxib relative to diclofenac has
signiﬁcantly lower hospitalization costs per patient, and
the total costs for the two treatments are not signiﬁcantly
different, indicating that the superior safety beneﬁts with
valdecoxib might be achieved without an increase in total
treatment costs.
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OBJECTIVES: To evaluate the cost-effectiveness of etori-
coxib, a new selective Cox-2 inhibitor, in the treatment
of acute gouty arthritis compared with indomethacin in
the United Kingdom. METHODS: Using a recent clinical
trial comparing etoricoxib with indomethacin in the treat-
ment of acute gouty arthritis, a Markov model was built
based on four 8-day treatment cycles spread over four
years. In the trial, etoricoxib and indomethacin demon-
strated equivalent efﬁcacy but adverse event (AE) and
treatment discontinuation rates favored etoricoxib. In cal-
culating the total cost for each type of AE, its frequency
in the trial was taken into account. The medical treatment
of AEs and the average predicted probability of seeking
treatment were obtained from expert opinion and used
for the base case analysis. In the model, all patients suf-
fering an AE or discontinuing treatment selected a differ-
ent treatment for their next gout attack. The model
further assumed a general practitioner would treat all
patients and that an AE could necessitate one additional
GP visit. RESULTS: After one cycle of treatment the
incremental cost per patient successfully treated with
etoricoxib (no AE or discontinuation), including drug
therapy costs, was £15.43, decreasing to £6.27 over 4
cycles of treatment. CONCLUSION: In this study, etori-
coxib was a cost-effective alternative to indomethacin for
treatment of acute gouty arthritis based on the modelling
calculations using published clinical trial data and con-
servative assumptions regarding the treatment of AEs.
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OBJECTIVE: To determine the incremental cost-
effectiveness of COX-2-selective versus non-selective non-
steroidal anti-inﬂammatory drugs (NSAIDs) in relation 
to bleeding in a cohort of coumarin users. METHODS:
A pharmacoeconomic evaluation was linked to a case-
control design within an observational study in con-
comitant NSAID and coumarin users (with versus
without bleeding). Medical costs associated with bleeding
as well as costs associated with NSAID-use were deter-
mined, according to the Dutch guideline prices and
Health care tariffs. Rofecoxib, meloxicam, and nabume-
tone were considered to be COX-2-selective. Total costs
were calculated and compared for two hypothetical sce-
narios in which patients would use either COX-2-
selective NSAIDs or non-selective NSAIDs. Sensitivity
analyses were performed varying both the Odds Ratio
(OR) and costs of NSAIDs and bleedings. RESULTS:
A total of 1491 bleeding complications were detected
among 4400 coumarin users. Of the bleeders, 14.8% 
(n = 221) used a non-selective (96.1%) or COX-2-
selective (3.9%) NSAID. The OR for bleeding was 3.07
(95% CI 1.18–8.03) for non-selective versus COX-2-
selective NSAIDs. The mean cost of a bleeding was €478.
Factoring in the excess costs of COX-2-selective over
non-selective NSAID-use resulted in net savings of
€53,786. In the sensitivity analysis, cost savings remained,
except for situations with the OR in the lower range of
the conﬁdence interval (1.18–1.26). CONCLUSIONS: In
coumarin users, the reduction of bleeding complications
by the more expensive COX-2-selective inhibitors (com-
pared with non-selective NSAIDs) is also associated with
medical cost savings.
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OBJECTIVES: To assess the average prescribed daily
dose and cost of the two reimbursed coxibs, rofecoxib
and celecoxib, in Norway. Given the drugs’ different price
structures, prescribed number of tablets and strength
impact the daily treatment cost differentially. As a pre-
requisite for continued general reimbursement for rofe-
coxib and celecoxib from July 1, 2003, the Norwegian
Ministry of Health required post-marketing data regard-
ing prescription patterns in clinical practice to further
evaluate the drugs’ relative cost effectiveness. The Min-
istry’s re-evaluation will be based on this and other
studies. METHODS: All accessible physicians within the
ﬁeld of rheumatology (specialists) in Norway were invited
to prospectively register their prescriptions of reimbursed
coxibs for patients with Rheumatoid Arthritis (RA)
and/or Osteoarthritis (OA), over a period of 2 months
(October to December 2002). Data from registration
forms and patient records were collected through per-
